Distinct promoter usage and alternative splicing of MDM2 has been reported in breast cancer cell lines and breast tumor tissues leading to aberrant expression of MDM2 disrupting TP53 pathway in breast tumors (Lukas et al. 2001; Okumura et al. 2002). Here, MDM2 is linked to breast cancer.